EP4272837A3 - Cellules car-t ciblant bcma pour le traitement de myélomes multiples - Google Patents

Cellules car-t ciblant bcma pour le traitement de myélomes multiples Download PDF

Info

Publication number
EP4272837A3
EP4272837A3 EP23190869.0A EP23190869A EP4272837A3 EP 4272837 A3 EP4272837 A3 EP 4272837A3 EP 23190869 A EP23190869 A EP 23190869A EP 4272837 A3 EP4272837 A3 EP 4272837A3
Authority
EP
European Patent Office
Prior art keywords
car
treatment
multiple myeloma
cells against
against bcma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23190869.0A
Other languages
German (de)
English (en)
Other versions
EP4272837A2 (fr
Inventor
Álvaro URBANO ISPIZUA
Beatriz MARTÍN ANTONIO
Lorena PÉREZ AMILL
Guillermo SUÑE RODRIGUEZ
Manel JUAN OTERO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de Barcelona UB
Hospital Clinic de Barcelona
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Original Assignee
Universitat de Barcelona UB
Hospital Clinic de Barcelona
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat de Barcelona UB, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer filed Critical Universitat de Barcelona UB
Publication of EP4272837A2 publication Critical patent/EP4272837A2/fr
Publication of EP4272837A3 publication Critical patent/EP4272837A3/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
EP23190869.0A 2019-08-02 2020-08-03 Cellules car-t ciblant bcma pour le traitement de myélomes multiples Pending EP4272837A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382673 2019-08-02
EP20757544.0A EP4007777B1 (fr) 2019-08-02 2020-08-03 Cellules car-t ciblant bcma pour le traitement de myélomes multiples
PCT/EP2020/071831 WO2021023721A1 (fr) 2019-08-02 2020-08-03 Lymphocytes t car dirigés contre bcma pour le traitement du myélome multiple

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP20757544.0A Division EP4007777B1 (fr) 2019-08-02 2020-08-03 Cellules car-t ciblant bcma pour le traitement de myélomes multiples
EP20757544.0A Division-Into EP4007777B1 (fr) 2019-08-02 2020-08-03 Cellules car-t ciblant bcma pour le traitement de myélomes multiples

Publications (2)

Publication Number Publication Date
EP4272837A2 EP4272837A2 (fr) 2023-11-08
EP4272837A3 true EP4272837A3 (fr) 2024-02-28

Family

ID=67658496

Family Applications (2)

Application Number Title Priority Date Filing Date
EP23190869.0A Pending EP4272837A3 (fr) 2019-08-02 2020-08-03 Cellules car-t ciblant bcma pour le traitement de myélomes multiples
EP20757544.0A Active EP4007777B1 (fr) 2019-08-02 2020-08-03 Cellules car-t ciblant bcma pour le traitement de myélomes multiples

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20757544.0A Active EP4007777B1 (fr) 2019-08-02 2020-08-03 Cellules car-t ciblant bcma pour le traitement de myélomes multiples

Country Status (18)

Country Link
US (1) US12509525B2 (fr)
EP (2) EP4272837A3 (fr)
JP (1) JP7729561B2 (fr)
AU (1) AU2020325690A1 (fr)
CA (1) CA3148930A1 (fr)
DK (1) DK4007777T5 (fr)
ES (1) ES2971033T3 (fr)
FI (1) FI4007777T3 (fr)
HR (1) HRP20240037T1 (fr)
HU (1) HUE064890T2 (fr)
LT (1) LT4007777T (fr)
PL (1) PL4007777T3 (fr)
PT (1) PT4007777T (fr)
RS (1) RS65094B1 (fr)
SI (1) SI4007777T1 (fr)
SM (1) SMT202400013T1 (fr)
WO (1) WO2021023721A1 (fr)
ZA (1) ZA202201166B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506468A (ja) * 2022-02-09 2025-03-11 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 免疫関連障害を標的とする抗ｂｃｍａ ｃａｒ、その組成物及び方法
EP4378953A1 (fr) * 2022-12-02 2024-06-05 Universitat de Barcelona Fraction de ciblage de cd29 pour le traitement du cancer positif de cd29
WO2025141187A1 (fr) * 2023-12-29 2025-07-03 Fundación Para La Investigación Biomédica Del Hospital Universitario 12 De Octubre Lymphocytes t exprimant des anticorps bispécifiques anti-bcma/anti-cd3 et leurs utilisations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017211900A1 (fr) * 2016-06-07 2017-12-14 Max-Delbrück-Centrum für Molekulare Medizin Récepteur d'antigène chimère et cellules t-car se liant à bcma
CN108004259A (zh) * 2016-11-02 2018-05-08 上海恒润达生生物科技有限公司 靶向b细胞成熟抗原的嵌合抗原受体及其用途
CN108285489A (zh) * 2017-01-09 2018-07-17 上海恒润达生生物科技有限公司 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
US20180325955A1 (en) * 2017-05-12 2018-11-15 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0768377A1 (fr) 1988-09-02 1997-04-16 Protein Engineering Corporation Production et sélection de protéines de liaison diversifiées de recombinaison
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (fr) 1990-07-10 2002-10-01 Gregory P. Winter Methodes de production de membres de paires de liaison specifiques
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1994026290A1 (fr) 1993-05-07 1994-11-24 Immunex Corporation Cytokine denommee ligand 4-1bb et recepteur humain s'y fixant
NO3051026T3 (fr) 2011-10-21 2018-07-28
ES2937015T3 (es) * 2012-11-01 2023-03-23 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Anticuerpo contra CD269 (BCMA)
ES2546743B1 (es) 2014-03-28 2016-07-07 Institut D'investigació Biomèdica De Bellvitge (Idibell) Marcadores mitocondriales de enfermedades neurodegenerativas
KR102526945B1 (ko) 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
RS64455B1 (sr) 2018-03-13 2023-09-29 Sepsia Therapeutics S L Peptidi koji vezuju bakterije, za lečenje infektivnih bolesti i povezanih inflamatornih procesa

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017211900A1 (fr) * 2016-06-07 2017-12-14 Max-Delbrück-Centrum für Molekulare Medizin Récepteur d'antigène chimère et cellules t-car se liant à bcma
CN108004259A (zh) * 2016-11-02 2018-05-08 上海恒润达生生物科技有限公司 靶向b细胞成熟抗原的嵌合抗原受体及其用途
CN108285489A (zh) * 2017-01-09 2018-07-17 上海恒润达生生物科技有限公司 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
US20180325955A1 (en) * 2017-05-12 2018-11-15 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARINA MARTINEZ ET AL: "CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment", FRONTIERS IN IMMUNOLOGY, vol. 10, 5 February 2019 (2019-02-05), pages 12800128, XP055727858, DOI: 10.3389/fimmu.2019.00128 *

Also Published As

Publication number Publication date
EP4007777B1 (fr) 2023-10-11
JP7729561B2 (ja) 2025-08-26
FI4007777T3 (fi) 2024-01-11
CA3148930A1 (fr) 2021-02-11
SI4007777T1 (sl) 2024-03-29
ES2971033T3 (es) 2024-06-03
WO2021023721A1 (fr) 2021-02-11
US12509525B2 (en) 2025-12-30
HRP20240037T1 (hr) 2024-03-29
US20220267459A1 (en) 2022-08-25
DK4007777T5 (da) 2024-08-05
AU2020325690A1 (en) 2022-03-03
EP4272837A2 (fr) 2023-11-08
PL4007777T3 (pl) 2024-03-11
PT4007777T (pt) 2024-01-12
SMT202400013T1 (it) 2024-03-13
DK4007777T3 (da) 2024-01-15
EP4007777A1 (fr) 2022-06-08
LT4007777T (lt) 2024-02-12
JP2022542443A (ja) 2022-10-03
HUE064890T2 (hu) 2024-04-28
ZA202201166B (en) 2022-10-26
RS65094B1 (sr) 2024-02-29

Similar Documents

Publication Publication Date Title
PH12021550419A1 (en) Methods of making chimeric antigen receptor-expressing cells
WO2021108661A3 (fr) Récepteurs antigéniques chimériques et leurs utilisations
WO2020047449A3 (fr) Procédés de fabrication de cellules exprimant un récepteur d'antigène chimère
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
WO2020061478A3 (fr) Méthodes de purification d'anticorps hétérodimères multispécifiques
MX2022005152A (es) Uso de receptores de antigenos quimericos anti-bcma.
AU2016259730A8 (en) Claudin-18.2-specific immunoreceptors and T cell epitopes
EP4368641A3 (fr) Récepteurs antigéniques chimériques d'antigène de myélome kappa et leurs utilisations
ECSP19031545A (es) Composiciones de células t con car anti-bcma
WO2020121195A8 (fr) Anticorps trem2 et leurs utilisations
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
WO2017152085A8 (fr) Polythérapie avec des anticorps anti-cd73
MX2020006818A (es) Receptores quimericos multiespecificos que comprenden un dominio nkg2d, y metodos de uso de los mismos.
MX2018013038A (es) Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
EP4223269A3 (fr) Utilisations de récepteurs antigéniques chimériques anti-bcma
SG10201900931XA (en) Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
AU2017286676A8 (en) Purification of multispecific antibodies
WO2015127136A3 (fr) Anticorps monoclonaux anti-ebola
SG10201900455YA (en) Bcma chimeric antigen receptors
NZ741067A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
MX2025003852A (es) Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion
AU2013232386A8 (en) Treatment of multiple sclerosis with anti-CD19 antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 4007777

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20240122BHEP

Ipc: C07K 14/725 20060101ALI20240122BHEP

Ipc: A61K 39/00 20060101ALI20240122BHEP

Ipc: A61P 35/02 20060101AFI20240122BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240828

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20260324